Sanofi-Aventis, Regeneron Expand Partnership Wednesday, November 11, 9:33 AM ET
Sanofi-Aventis (NYSE:SNY) and Regeneron (NASDAQ:REGN) have extended their antibody marketing partnership through 2017.
Sanofi has agreed to increase its funding of Regeneron’s therapeutic monoclonal antibody research by $60 million per year, for a total of $160 million annually.
The partnership, under which the two companies hope to develop five antibodies per year, would have expired in 2012.
Since the partnership began in 2007, the companies have brought four treatments into clinical development, working, for example, as pain medications.
Any ideas and opinions presented in all Market News Video clips are for informational and educational purposes
only, and do not reflect the opinions of BNK Invest, Inc. or any of its affiliates, subsidiaries or partners.
In no way should any content contained herein be interpreted to represent trading or investment advice.
None of the information contained herein constitutes a recommendation that any particular security, portfolio,
transaction, or investment strategy is suitable for any specific person. All viewers agree that under no
circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held
liable for any loss or damage caused by your reliance on information obtained. Read Full Disclaimer.
